Asia Pacific BNP and NT-proBNP Market Size, Share & Industry Trends Analysis Report by Location of Testing, Application, Country and Growth Forecast, 2022-2028

The Asia Pacific BNP and NT-proBNP Market should witness market growth of 12.4% CAGR during the forecast period (2022-2028).

Natriuresis, vasodilatation,and diuresis are the major effects of BNP. The natriuretic peptide receptor C (NPR-C), responsible for regulating receptor-mediated lysosomal and endocytosis degradation, binds to BNP and clears it from the body. Neutral endopeptidases, which are found in cells present in the vascular walls and renal tubular cells, also break down BNP. NTproBNP, a substance with a half-life of about 120 minutes compared to 20 minutes for BNP, is considered to be excreted by the kidney.

Although NT-proBNP is eliminated in a 1:1 ratio to BNP, the differences in half-lives and clearance processes account for the significantly larger amounts of NT-proBNP in serum. BNP and NT-proBNP levels have been demonstrated to correlate favorably with echocardiographic abnormalities in CKD patients. Both ventricular dysfunction/hypertrophy and volume overload have been implicated in increased BNP andNT-proBNP in dialysis patients.

Asia Pacific is anticipated to grow significantly during the forecast period. Government funding for specific diagnosis and other research has increased due to the rising incidence of CVDs (cardiovascular diseases). In comparison to other developing nations of the region, India has a considerable prevalence of CVDs. The high prevalence of the disease has facilitated a rise in the need for BNP and NT-proBNP diagnostics to aid in the early detection, assessment, and treatment of CVDs. Throughout the forecast period, the BNP and NT-proBNP market in the Asia Pacific region is expanding significantly.

The China market dominated the Asia Pacific Bnp And Ntprobnp Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $181.3 Million by 2028. The Japan market is estimated to grow a CAGR of 11.7% during (2022-2028). Additionally, the Indian market would experience a CAGR of 13.1% during (2022-2028).

Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on Application, the market is segmented into Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.

Scope of the Study

By Location of Testing

• Point of Care Testing
• Laboratory Testing

By Application

• Myocardial Infarction
• Acute Coronary Syndrome (ACS)
• Congestive Heart Failure (CHF)
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Siemens AG
• Danaher Corporation
• Gentian Diagnostics ASA
• PerkinElmer, Inc.
• BioMérieux S.A.
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F.Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
• Scripps Laboratories

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free